JBM HEALTHCARE2161.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, JBM HEALTHCARE (2161.HK) trades at a P/E of 6.54x, P/B of 1.22x, P/S of 1.58x, and a dividend yield of 13.28%.
Longitudinal percentile comparison: P/E sits at the 11th percentile over the trailing 10Y window (vs. 20th percentile over 3Y); P/B sits at the 59th percentile over the trailing 10Y window (vs. 37th percentile over 3Y); P/S sits at the 26th percentile over the trailing 10Y window (vs. 34th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 29th percentile within its industry and the 27th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 13.28%, ranking at the 94th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 48.0 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. JBM HEALTHCARE operates in the Traditional Chinese Medicine Production sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2161 · SEHK: 2161 · 2161
Want the full picture on whether JBM HEALTHCARE (2161.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 6.54 | ||||||
| P/B (MRQ) | 1.22 | ||||||
| P/S (TTM) | 1.58 | ||||||
| Dividend Yield | 13.28% | ||||||
| Buyback + Div Yield | 13.28% |